References
- Aoki KR. Evidence for
antinociceptive activity of botulinum toxin type A in pain management.
Headache 43(Suppl
1): S9-15, 2003
- Meng J, Wang J, Lawrence G,
Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory
neurons and inhibition by botulinum toxins reflects their
anti-nociceptive potential. J Cell Sci 120(16):1864-74, 2007
- Thambar
S, Kulkarni S, Amstrong S, Nikolarakos D. Botulinum toxin in the
management of temporomandibular disorder: a systematic review. Br J
Oral Maxillofac Surg. Mar 03, 2020 [Epub ahead of print]
- Ernberg M, Hedenberg-Magnusson
B, List T, Svensson P. Efficacy of botulinum toxin type A for
treatment of persistent myofascial TMDpain: a randomized, controlled,
double-blind multicenter study. Pain 152(9):1988-96, 2011
- Suvinen TI, Malmberg J, Forster
C, Kemppainen P. Postural and dynamic masseter and anterior temporalis
muscle EMG repeatability in serial assessment. J Oral Rehabil.
36(11):814-20, 2009
- Ohrbach R, editor. Diagnostic
Criteria for Temporomandibular Disorders: Assessment Instruments.
Version 15May2016.[Diagnostiset Kriteerit Purentaelimistön Kivuille
ja Toimintahäiriöille (DC/TMD-FIN): Tutkimusinstrumentit: Finnish
Version 25May2016] Sipilä K, Suvinen T,
Trans.www.rdc-tmdinternational.org (Accessed on July 1, 2020).
- Suvinen T, Rantala M, Ahlberg J,
Könönen M. RDCTMD_FIN.
www.rdc-tmdinternational.org
(Accessed on July 1, 2020).
- Pihut M, Wisniewska G, Majewski
P,
Gronkiewicz
K, S
Majewski. Measurement of occlusal forces in the therapy of functional
disorders with the use of botulinum toxin type A. J Physiol Pharmacol
60(Suppl 8): 113-6, 2009
- Lee HJ, Kim SJ, Lee KJ, Yu HS,
Baik HS. Repeated injections of botulinum toxin into the masseter
muscle induce bony changes in human adults: A longitudinal study.
Korean J Orthod. 2017;47(4):222-228